Cargando…
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
BACKGROUND: 2020 World Health Organization Classification of Female Genital Tumors removed ovarian seromucinous carcinoma as a distinct entity and recategorized it as ovarian endometrioid carcinoma with mucinous differentiation according to its pathological features. The aim of this study was to fin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862510/ https://www.ncbi.nlm.nih.gov/pubmed/36670456 http://dx.doi.org/10.1186/s13048-023-01100-w |
_version_ | 1784875109942558720 |
---|---|
author | Hu, Yi Fu, Kun Liu, Huining He, Qiongqiong Qiu, Xiaoqin Yang, Wenqing Zhang, Yu |
author_facet | Hu, Yi Fu, Kun Liu, Huining He, Qiongqiong Qiu, Xiaoqin Yang, Wenqing Zhang, Yu |
author_sort | Hu, Yi |
collection | PubMed |
description | BACKGROUND: 2020 World Health Organization Classification of Female Genital Tumors removed ovarian seromucinous carcinoma as a distinct entity and recategorized it as ovarian endometrioid carcinoma with mucinous differentiation according to its pathological features. The aim of this study was to find whether ovarian seromucinous carcinoma truly represented a distinct category of ovarian tumors or an analogue of ovarian endometrioid carcinoma. METHODS: Twelve patients diagnosed with ovarian seromucinous carcinoma and received surgery at the Xiangya Hospital from January 2010 to December 2019 were included in this study. Clinicopathological features such as clinical symptoms, serological indicators, surgical information, postoperative findings, chemotherapy sensitivity, follow-up information, HE staining and IHC staining images and other clinicopathologic features were collected. Using t-test and Kaplan Meier to perform statistical analysis. Pathological review was conducted using the 2014 World Health Organization criteria. All pathological diagnoses were reviewed by two experienced pathologists. RESULTS: The age of 12 patients diagnosed with ovarian seromucinous carcinoma ranged from 23 to 68 years, with a median age of 46.8 years. Serum level of CA125 was elevated in 10 patients, and CA125/CEA ratio was less than 25 in 6 patients. Eleven patients underwent radical ovarian cancer surgery, and one patient underwent fertility preservation surgery. The progression free survival and overall survival of ovarian seromucinous carcinoma is 46.8 months and 50.2 months. Kaplan-Meier survival curve showed that the prognosis of ovarian seromucinous carcinoma and ovarian endometrioid carcinoma was significantly different (P = 0.03). The prognosis of ovarian seromucinous carcinoma and ovarian mucinous carcinoma was similar. CONCLUSION: Although ovarian seromucinous carcinoma and ovarian endometrioid carcinoma are similar in pathologic morphology, their clinical features and prognosis are significantly different. The signs, serum biomarker and prognosis of the ovarian seromucinous carcinoma are similar with ovarian mucinous carcinoma. Therefore, ovarian seromucinous carcinoma is not suitable to be directly classified as ovarian endometrioid carcinoma. |
format | Online Article Text |
id | pubmed-9862510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98625102023-01-22 Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer? Hu, Yi Fu, Kun Liu, Huining He, Qiongqiong Qiu, Xiaoqin Yang, Wenqing Zhang, Yu J Ovarian Res Research BACKGROUND: 2020 World Health Organization Classification of Female Genital Tumors removed ovarian seromucinous carcinoma as a distinct entity and recategorized it as ovarian endometrioid carcinoma with mucinous differentiation according to its pathological features. The aim of this study was to find whether ovarian seromucinous carcinoma truly represented a distinct category of ovarian tumors or an analogue of ovarian endometrioid carcinoma. METHODS: Twelve patients diagnosed with ovarian seromucinous carcinoma and received surgery at the Xiangya Hospital from January 2010 to December 2019 were included in this study. Clinicopathological features such as clinical symptoms, serological indicators, surgical information, postoperative findings, chemotherapy sensitivity, follow-up information, HE staining and IHC staining images and other clinicopathologic features were collected. Using t-test and Kaplan Meier to perform statistical analysis. Pathological review was conducted using the 2014 World Health Organization criteria. All pathological diagnoses were reviewed by two experienced pathologists. RESULTS: The age of 12 patients diagnosed with ovarian seromucinous carcinoma ranged from 23 to 68 years, with a median age of 46.8 years. Serum level of CA125 was elevated in 10 patients, and CA125/CEA ratio was less than 25 in 6 patients. Eleven patients underwent radical ovarian cancer surgery, and one patient underwent fertility preservation surgery. The progression free survival and overall survival of ovarian seromucinous carcinoma is 46.8 months and 50.2 months. Kaplan-Meier survival curve showed that the prognosis of ovarian seromucinous carcinoma and ovarian endometrioid carcinoma was significantly different (P = 0.03). The prognosis of ovarian seromucinous carcinoma and ovarian mucinous carcinoma was similar. CONCLUSION: Although ovarian seromucinous carcinoma and ovarian endometrioid carcinoma are similar in pathologic morphology, their clinical features and prognosis are significantly different. The signs, serum biomarker and prognosis of the ovarian seromucinous carcinoma are similar with ovarian mucinous carcinoma. Therefore, ovarian seromucinous carcinoma is not suitable to be directly classified as ovarian endometrioid carcinoma. BioMed Central 2023-01-20 /pmc/articles/PMC9862510/ /pubmed/36670456 http://dx.doi.org/10.1186/s13048-023-01100-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hu, Yi Fu, Kun Liu, Huining He, Qiongqiong Qiu, Xiaoqin Yang, Wenqing Zhang, Yu Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer? |
title | Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer? |
title_full | Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer? |
title_fullStr | Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer? |
title_full_unstemmed | Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer? |
title_short | Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer? |
title_sort | ovarian seromucinous carcinoma: an independent epithelial ovarian cancer? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862510/ https://www.ncbi.nlm.nih.gov/pubmed/36670456 http://dx.doi.org/10.1186/s13048-023-01100-w |
work_keys_str_mv | AT huyi ovarianseromucinouscarcinomaanindependentepithelialovariancancer AT fukun ovarianseromucinouscarcinomaanindependentepithelialovariancancer AT liuhuining ovarianseromucinouscarcinomaanindependentepithelialovariancancer AT heqiongqiong ovarianseromucinouscarcinomaanindependentepithelialovariancancer AT qiuxiaoqin ovarianseromucinouscarcinomaanindependentepithelialovariancancer AT yangwenqing ovarianseromucinouscarcinomaanindependentepithelialovariancancer AT zhangyu ovarianseromucinouscarcinomaanindependentepithelialovariancancer |